文献速递乳腺癌放疗放疗物理与技术

乳腺癌区域淋巴结照射:依据Z0011、AMAROS、EORTC 10981与MA-20靶区设计的剂量评估

Irradiation of regional lymph node areas in breast cancer - Dose evaluation according to the Z0011, AMAROS, EORTC 10981-22023 and MA-20 field design.
PubMed 文献 · Radiother Oncol · 2019-09-17

本研究将235例患者的580个F18-FDG-PET/CT阳性淋巴结转移灶刚性及非刚性配准至三套模板CT,并按MA.20、EORTC、AMAROS与Z0011试验方案设计左右侧治疗计划,评估ESTRO指南勾画的临床靶体积及580个淋巴结的剂量分布。结果显示靶区淋巴结剂量覆盖差异较大(26.8±17.3 Gy至53.0±1.8 Gy),取决于计划设计与患者体型,且无一计划设计对全部淋巴引流系统实现完整覆盖;高切线照射在腋窝I、II水平的剂量分布与AMAROS野设计相似。

要点

  • 各随机试验计划设计对淋巴引流系统均未实现完整剂量覆盖。
  • 靶区淋巴结剂量覆盖随计划设计与患者体型变化,范围26.8±17.3 Gy至53.0±1.8 Gy。
  • 高切线照射在腋窝I、II水平的剂量分布与AMAROS野设计相似。

核心结论

  • 并非所有患者都需包含整个淋巴系统才能复现随机淋巴结照射试验的肿瘤学获益。
  • 基于MA.20试验的剂量重算,可考虑对选定高危患者包含腋窝II水平并扩展锁骨上临床靶体积。
  • 结果支持既往假设,即Z0011试验中单独前哨淋巴结活检后的良好结果可能归因于照射。

研究设计与样本

  • 将235例患者的580个F18-FDG-PET/CT阳性淋巴结转移灶刚性及非刚性配准至标准、肥胖与瘦削三套模板CT。
  • 按ESTRO指南勾画淋巴结临床靶体积,并依MA.20、EORTC、AMAROS与Z0011试验方案设计左右侧治疗计划。
  • 评估ESTRO临床靶体积及580个淋巴结的剂量分布。

主要发现

  • 靶区淋巴结区域(ESTRO临床靶体积与淋巴结)剂量覆盖随计划设计与患者体型变化,范围为26.8±17.3 Gy至53.0±1.8 Gy。
  • 无任何治疗计划设计对淋巴引流系统实现完整剂量覆盖。
  • 高切线照射在腋窝I、II水平的剂量分布与AMAROS野设计相似。

临床怎么用

  • 可依据MA.20试验剂量重算结果,对选定高危患者考虑包含腋窝II水平并扩展锁骨上临床靶体积。
  • 并非所有患者都需照射整个淋巴系统以复现随机试验的肿瘤学获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The purpose of this study was to estimate the dose distribution from randomized trials (MA.20, EORTC 22922-10925 (EORTC), AMAROS and the Z0011 trial) on lymph node (LN) irradiation on a large LN atlas. METHODS: 580 F18-FDG-PET/CT positive LN metastases of 235 patients were transferred rigidly and non-rigidly to three "template CTs" (standard, obese and slender patient). Further, the LN clinical target volumes (CTVs) were contoured according to the ESTRO-guidelines. Treatment plans were designed (each for the left and right side) for all patients based on the study protocols of the MA.20, EORTC, AMAROS and Z0011 trial. Subsequently, the dose distribution in the ESTRO-CTVs and in the 580 LNs were assessed. RESULTS: Our results reveal variable dose coverage (26.8 ± 17.3 Gy-53.0 ± 1.8 Gy) in the targeted LN areas (ESTRO-CTV and LN) in dependence of the treatment planning design and the patients' body shape. None of the treatment plan designs provided full dose coverage to the lymphatic drainage system. High tangent irradiation resulted in a similar dose distribution in L I and II compared to the AMAROS field design. CONCLUSION: Inclusion of the entire lymphatic system may not be necessary for all patients to reproduce the oncologic benefit shown in the randomized LN-irradiation trials. Inclusion of axillary level II and extension of the supraclavicular CTV can be considered in selected high-risk patients, based on dose recalculation of the MA.20 trial. Further, our results amplify earlier assumptions that irradiation may have accounted for the good results after SLND alone in the Z0011 trial.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Borm KJ, Oechsner M, Düsberg M, et al. Irradiation of regional lymph node areas in breast cancer - Dose evaluation according to the Z0011, AMAROS, EORTC 10981-22023 and MA-20 field design. Radiother Oncol. 2019. PMID: 31540747. doi:10.1016/j.radonc.2019.08.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。